News | January 18, 2026
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
Subscribe To Our Newsletter & Stay Updated
